THE BE T
Multimedia Highlights
From the CardioSource WorldNews YouTube Channel | Scan the QR code to watch the full video
Mini, Micro, Nano: Cardiology’s ‘Fantastic Journey’ to Miniaturization
Treatment Persistence with
Anticoagulation Therapy for AF
PEAGASUS Long-term Results:
Ticagrelor in Patients with Prior-MI
Uday Kumar, MD: “The basic philosophy
is that, when you want to solve unmet
medical needs, focus on the need and not
the technology. So much of what happens
in the consumer [field] outside of the health
care field is ‘I have a gadget, I have a smart
phone, what can I do with it?’ When you
are making decisions as an individual, that
might work. But in health care, [you need to
understand] the entire milieu.”
Craig Coleman, PharmD: “The reason this is
so important is that these patients are at high
risk for strokes, and strokes are really bad;
they are associated with a lot of disability and
a lot of cost to the U.S. health care system.
It’s incredibly important that we try to prevent
these strokes, and anticoagulation is key in
patients with [AF] patients.”
Steve Zelenkofske, DO: “The patients who
stayed on the Brilinta therapy, they continued
to show a benefit. There was a 21% reduction
compared to those who continued the
therapy. There is a benefit for staying on and
maintaining therapy in those patients.”
ATOMIC-AHF: Omecamtiv Mecarbil
in Acute HF
In-hospital Acute Kidney Injury
and Long-term Outcomes in Survivors
of ACS
Identifying Better Ways to Diagnose
and Manage Patients with Cryptogenic
Stroke
Purav Mody, MD: “Unsurprisingly, we
found that acute kidney injury [AKI] is fairly
common; in our analysis, we found at least
7% of the patients admitted with an MI or ACS
event tended to have an AKI event. Seven
percent of millions of patients is a large
number.”
Mary Ann Bauman, MD: “What we’re trying
to do is raise awareness of cryptogenic
stroke and to determine the appropriate
protocols so that everyone, wherever you are
in this country, will get the same evaluation.
What we would like to do is take cryptogenic
stroke—which means a stroke of unknown
cause—and make it a known cause.”
John Teerlink, MD: “[In] stable healthy
volunteers, in stable HF patients, and then in
acute HF patients, and across the board, in
all of those studies, omecamtiv mecarbil was
able to have its pharmacological signature of
increasing systolic ejection time and having
other improvements in cardiac performance.”
14
CardioSource WorldNews
March 2016